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Abstract: 
 
Introduction: Surgical benefits for renal cell carcinoma must be weighed against competing 
causes of mortality, especially in the elderly patient population. We used a large cancer registry 
to evaluate the impact of patient and cancer specific factors on 90-day mortality (90DM).  A 
nomogram to predict the odds of short-term mortality was created. 
 
Materials and Methods: The National Cancer Database was queried to identify all patients with 
clinically localized, non-metastatic disease treated with partial or radical nephrectomy.  Using a 
random sample of 60%, multiple logistic regression with 90DM outcomes was performed to 
identify pre-operative variables associated with mortality. Variables included age, sex, race, 
comorbidity score, tumor size, and presence of a thrombus.  A nomogram was created and tested 
on the remaining 40% of patients to predict 90DM.   
 
Results: 183,407 patients met inclusion criteria.  Overall 90DM for the cohort was 1.9%. All pre-
operative variables significantly influenced the risk of 90DM.  Patient age was by far the 
strongest predictor.  Nomogram scores ranged from 0-12.  Compared to patients with 0-1 points, 
those with 2-3 (OR 2.89, 2.42-3.46; p < 0.001), 4-5 (OR 6.25, 5.26-7.43; p < 0.001), and > 6 (OR 
12.86, 10.83-15.27; p < 0.001) were at incrementally significantly higher odds of 90DM.  Being 
>80 years of age alone placed patients into the highest risk of surgical mortality.  
 
Conclusions:  Management of localized kidney cancer must consider competing causes of 
mortality, especially in elderly patients with multiple co-morbidities.  We present a preoperative 
tool to calculate risk of surgical short-term mortality to aid surgeon-patient counseling.  
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1.  Introduction:  
Kidney cancer is the 8th leading cancer diagnosis in the United States with an estimated 63,990 
of new cases resulting in 14,400 deaths based on 2016 data (1).   In contrast to many of the other 
most commonly diagnosed malignancies, the incidence of kidney cancer has risen over the last 
few decades in men and women of every racial and ethnic group (2).  The rise in incidence of 
kidney cancer has coincided with a downward drift stage migration likely secondary to the more 
frequent diagnosis of small, incidental renal masses on cross-sectional imaging (3-6).  This rise 
in incidence, however, has not been observed in conjunction with a decrease in mortality despite 
increases in surgical treatment (5).  In fact, in some studies, mortality from renal cell cancer has 
risen calling into question current treatment paradigms thus stressing appropriate patient 
selection for operative procedures (2,5,7). 
Surgical resection remains the gold standard therapy for patients with renal cell carcinoma. The 
survival benefit from surgery for renal cell carcinoma is variable and is dependent upon patient 
and disease specific factors.  Age and associated medical comorbidities weigh heavily on 
patient’s overall survival and short term surgical morbidity and mortality (8,9).  Tumor specific 
characteristics such as tumor grade, stage and local/metastatic extent confer different risks of 
morbidity and mortality (10).  Previously, various studies have evaluated predictors of short–
term surgical morbidity, mortality and long-term overall-survival (11-13).  These studies have 
been influential in pre-operative patient counseling. 
In our current study, we sought to expand on these previous studies to evaluate pre-operative 
patient and tumor specific variables to evaluate their impact on short-term surgical mortality.  
We hypothesized that age, tumor size and stage, gender, race and co-morbidity status affect 
short-term surgical mortality.  Using the National Cancer Database (NCDB), we evaluated the 
impact of these variables on 90-day mortality to develop a nomogram to predict the odds of 
short-term surgical mortality to help aid in patient counseling.  
2.  Materials and Methods: 
2.1 
Data Source: 
The NCDB is a joint cancer registry that was established in 1989 by the Commission on Cancer 
of the American College of Surgeons and the American Cancer Society.  The database serves as 
a comprehensive clinical surveillance resource for cancer care in the United States (14,15).  The 
NCDB captures >70% of all newly diagnosed cancer cases from over >1,500 Commission on 
Cancer-accredited cancer programs in the United States and Puerto Rico.  
2.2 
Study Population: 
The NCDB user file for renal cell carcinoma was queried from 2003-2011.  The American Joint 
Committee on Cancer staging system was used to identify patients with clinically localized, non-
metastatic renal cell carcinoma (cT1-4, N0, M0).  Patient’s with clinically suspected or 
histologically confirmed locally advanced or metastatic lesions (N+: 22,956; ≥M1: 40,580), 
upper-tract urothelial cell carcinoma (n=34,279) and who were not treated surgically were 
excluded (n=23,481).   Patients with incomplete Charlson-Deyo co-morbidity data (n=68,324), 
pathologic surgical staging (n=67,414), or 90-day mortality data (90DM) were excluded 
(n=35,446).  Ultimately, 183,407 met inclusion criteria. 
2.3 
Co-variables and Endpoints: 
90-day mortality was used as the primary endpoint for analysis.  Co-variables used to construct 
the multivariable model included pre-operative patient (age, gender, race and Charlson-Deyo co-
morbidity scores) and tumor specific variables (size and presence or absence of a thrombus) that 
were presumed known to the surgeon prior to the operation. Tumor size was used as a surrogate 
for tumor stage.  Since the NCDB incompletely captures radiographic involvement of the inferior 
vena cava (IVC) in clinical stage variables, we elected to use pathologic demonstration of an 
IVC thrombus as a reasonable presumption that its involvement would be known preoperatively 
in all cases with rare exceptions.  Finally, an exploratory analysis excluding patients with pT1 
disease was done to identify pre-operative predictors of 90DM in patients who would likely not 
be candidates for active surveillance. 
2.4 
Statistical Analysis:  
Descriptive analysis of the data was performed using Pearson's chi-squared test for categorical 
data, Student's t-test for continuous data, and the Mann–Whitney test in the case of non-normally 
distributed continuous data.  Using a random sample of 60% of the patients in the dataset, 
multivariable logistic regression with the outcome of 90DM was performed to identify pre-
operative variables associated with mortality.  Variables were determined a priori to be included 
in the model.  A nomogram was derived from the odds ratios in the logistic regression model and 
tested on the remaining 40% of patients in the dataset for ability to predict 90DM.  Area under 
the curve (AUC) was calculated for the original multivariable logistic regression model and for 
the tested model to confirm accuracy between the models.  All statistical calculations were 
completed in STATA 12.1 (STATA Corp. LP, College Station, TX). 
3. Results: 
183,407 patients with clinically localized renal cell carcinoma treated with either partial or 
radical nephrectomy met inclusion criteria.  The median age was 62 (IQR: 52-70).   Most of the 
patients were male (112,597, 61.4%) and white (155,771, 84.9%).  Most patients were classified 
as Charlson-Deyo co-morbidity index of 0 (70.6%) with few having extensive comorbidities 
(Charlson-Deyo index 2, 7.3%).   The distribution of tumor stage, as defined by TNM staging, 
was as expected with lower stage tumors being more common (I: 69%; II: 12%; III: 18%, IV: 
1%).  Most patients had low-grade tumors (I-II: 59.1%).  Despite the predominance of stage I 
and low-grade tumors, only 29.2% of patients underwent partial nephrectomy.  Overall, the 30 
(30DM) and 90-day mortality rates for the entire cohort were low at 0.9% and 1.9%, 
respectively.  These results and other baseline demographic, tumor specific and short-term 
mortality data separated by age (decade) of surgery can be visualized in Table 1.  
 
After separating patients into age category by decade, several findings were noted. Overall, 
18.6%, 25.4%, 28.6%, 20.6% and 6.8% of patients were aged ≤ 49, 50-59, 60-69. 70-79, and 
≥80, respectively. Predictably, increasing age was associated with increasing comorbidity scores.  
Twenty five percent and 9.3% of the oldest group of patients had Charlson-Deyo index scores of 
1 and 2, respectively, compared to only 14% and 3.9% of those aged ≤ 49 years (p< 0.001; p < 
0.001).  There was observed grade and stage migration as older patients were more likely to have 
higher grade and higher stage tumors compared to their younger counterparts (Figure 1 and 2).  
Additionally, surgical technique varied amongst age categories.  Octogenarians were more likely 
to be treated with radical nephrectomy compared to the younger groups (83.9% vs. 63.4-74.6%, 
p < 0.001).  In terms of short-term surgical mortality, older patients were more likely to 
experience 30DM and 90DM when compared to younger patients.  The risk of mortality was 
highest in those aged ≥80 years with 30-day and 90-day morality rates of 2.8% and 5.7%, 
respectively (Table 1).  90-day mortality rates amongst the different age groups can be seen in 
Figure 3.  
3.1 
Development of a Nomogram: 
A multivariable logistic regression model was built around pre-operative variables using our 
primary endpoint of 90DM in a random 60% sample of our study population.   All pre-operative 
variables included were independent predictors of 90DM (Table 2). Older patients had higher 
odds of dying during the post-operative period than younger patients (≥80 years old vs. ≤49, OR 
7.53 95% CI 6.19-9.16) as did patients with more co-morbid conditions (Charlson-Deyo 2 vs. 0, 
OR 2.37 95% CI 2.08-2.69).  Tumor size (≥10 cm vs < 4 cm, OR 4.06 95% CI 3.56-4.63) and 
presence or absence of a thrombus (Presence vs Absence, OR 1.90, 95% CI 1.66-2.17) were 
significant predictors of 90DM.  The AUC for the multivariable logistic regression model was 
0.7475.  
 
A nomogram score was given to each pre-operative variable based on the odds ratio from the 
regression analysis.  The highest score possible was 14. The median (IQR) nomogram score was 
1 (IQR: 0-2).  Twelve percent of patients had nomogram score of 6 or higher.  Nomogram 
groups were then made based on patient distribution (Table 3).  Figure 4 graphically depicts the 
multivariable effect of each variable on the risk of 90-day mortality.  This depicts the relative 
importance of age when compared to other pre-operative variables.  Age >80 pre-operatively was 
the biggest predictor of 90DM.  Octogenarians, based on age alone, were included in the highest 
nomogram group (nomogram score ≥ 6).   
3.2 
Testing of the Nomogram: 
Multivariable logistic regression analysis was run on the remaining 40% of the study population 
to confirm appropriate modeling and test internal validation.  In the 60% nomogram generation 
cohort, patients with 0-1 nomogram points compared with those with 2-3 (OR 2.89, 2.42-3.46; p 
< 0.001), 4-5 (OR 6.25, 5.26-7.43; p < 0.001), and >6 (OR 12.86, 10.83-15.27; p < 0.001) were 
at incrementally significantly higher odds of 90DM.  The AUC for the generation cohort model 
was 0.7211. The associations were confirmed in the 40% validation cohort.  In this group, 
compared to patients with 0-1 points, those with 2-3 (OR 3.49, 2.80-4.35; p < 0.001), 4-5 (OR 
6.82, 5.49-8.48; p <0.001) and >6 (OR 14.57, 11.75-18.08; p, <0.001) were at incrementally 
significantly higher odds of 90DM (Table 3). The AUC for the validation model based on the 
40% was 0.7221.  
3.3  
Risk Factors of 90-Day Mortality in patients with pT2-pT4 tumors 
An exploratory multivariate model excluding patients with pT1 tumors was built around our pre-
defined pre-operative variables.  This was done to investigate if age was still an important 
predictor in 90DM in patients who would likely not be candidates for active surveillance.  Once 
again, age was the greatest predictor of 90DM (Table 5).  
4. Discussion:  
Our research highlights trends in disease presentation, management and outcomes in patients 
with renal cell carcinoma who undergo surgical treatment.  Using a prospectively maintained 
national cancer registry, a large patient population (183,407 patients) was analyzed to make 
generalizable conclusions.  Increasing patient age corresponds with increasing tumor grade and 
stage. Correspondingly, increasing age was associated with the presence of more medical co-
morbidities. Elderly patients pose a difficult treatment dilemma given their increased risk of high 
grade and stage tumors and their competing risks of medical co-morbidities, important factors 
when optimizing management for patients who present with renal tumors (8,10).  This highlights 
the importance of appropriate patient selection and patient counseling, especially in the elderly 
when considering surgical candidacy.  We evaluated 90-day surgical mortality in patients 
undergoing partial or radical nephrectomy to evaluate predictors of short-term mortality.  
Compared to younger patients (<50), patients of advanced age were more likely to expire within 
the 30 and 90 days post-operatively.  Patient age was the most important predictor of peri-
operative mortality which far exceeded the influence of medical co-morbidities, tumor size or 
advanced clinical stage.  We believe that these findings highlight that patient age is a more 
important predictor of short-term mortality than tumor biology.  Using our data, we created a 
nomogram to help with pre-operative decision-making and patient counseling for all patients 
undergoing extirpative surgery for renal cell carcinoma with the goals of surgical cure.   
  
Previously, researchers used data from the National Cancer Institute Surveillance, Epidemiology 
and End Results (SEER) database to evaluate age and stage specific thirty-day mortality rates 
(TDM) after partial or radical nephrectomy.  In a cohort of 24,535 patients, TDM increased with 
patient age and stage and these two factors achieved independent predictor status on logistic 
regression analysis (12).  A second study evaluated TDM rates in patients undergoing 
nephrectomy in Great Britain.  In analysis of 21,380 procedures performed over a three-year 
period, increases in TDM were associated with increasing age, stage, estimated blood loss, 
operative time and performance status.  By including all patients treated surgically, patients with 
localized disease and metastatic disease were compared and, as expected, those with localized 
disease had lower odds of TDM than those undergoing cytoreductive nephrectomy (OR 0.31 
95% CI 0.18-0.54) (11).  These studies, and our current study, have a few notable differences.  
First, we elected to evaluate a group of patients with presumed non-metastatic disease where 
surgical intent was curative.  Including patients with known metastatic or lymph node positive 
disease is an extremely different cohort and the benefit of surgical intervention is dependent 
upon many clinical and radiographic variables as well as the ability for patients to receive 
adjuvant therapy (16,17).  Second, although we were unable to capture intraoperative surgical 
variables, we did not observe significant differences in outcomes with increasing severity of 
tumor biology relative to patient age.  Finally, we elected to use 90DM as a more comprehensive 
endpoint that includes data on all patients who demised with surgical intervention as the primary 
cause of death or at least an important contributor.   
 
Our analysis should be considered in the context of several limitations. The majority of 
limitations relate to data variables included in the National Cancer Database.  Unfortunately, the 
database does not report oncologic outcomes such as disease-free, cancer specific survival or 
cause of death. We instead chose to focus on thirty and ninety-day mortality acknowledging that 
the ideal decision-making tool would be one that weighs short term morbidity and mortality risk 
against long term cancer survival for each individual patient. Additionally, intraoperative details 
are not reported in the NCDB which could have influenced our findings. Because of the lack of 
preoperative clinical reporting, pathologic T3b or greater disease was used as surrogate for IVC 
involvement of the primary tumor with the assumption that IVC involvement would impart 
greater potential morbidity than tumor residing only in a branch or main renal vein.  The NCDB 
uses the Charlson-Deyo score to report patient comorbid conditions.  This method uses a 
weighted calculation based on the sum of the scores of comorbid conditions, which is an inexact 
method of determining comorbidity.  This further increases the heterogenicity of the cohort.  
Surgeries were completed over a 9-year period during which the use of minimally invasive 
approaches for surgical management of RCC was increasing.  Thus, operative year may have 
influenced 90DM, however, this was not considered in our multivariate analysis as it was not a 
patient or tumor specific variable.  Population databases include multiple surgeons with different 
levels of surgical experience which cannot be accounted for in our analysis.  Certainly, single 
surgeon or institution cohorts may report lower 90DM; however, we believe using population 
data to elucidate predictors of 90DM is more appropriate due to the generalizability of these 
results. Finally, a split validation assessment of our nomogram is not as robust as external 
validation on a separate patient population; however, results would be likely be similar using 
another large database or institutional records due to the fact that the NCDB captures >70% of 
newly diagnosed cases at over 1,500 hospitals in the United States.  These findings 
notwithstanding our dataset is the largest to describe both 30 and 90-day mortality rates in 
patients presenting with localized renal masses and the first to provide a useful nomogram tool 
for pre-operative counseling in this setting. 
  
We believe that our results will assist physicians in clinical-decision making and help guide 
patient counseling.  Deciding to operate on patients presenting with suspected renal cell 
carcinoma is not always easy, especially in older individuals. The results of the study should not 
be interpreted as a suggestion to not operate on older individuals with renal masses.  We 
advocate for a thoughtful physician-patient discussion on the competing risks of morbidity and 
mortality in this group.   Trends suggest that older patients with RCC are being operated on more 
frequently (18).  Much of this increase is due to the advent and acceptability of minimally 
invasive approaches with the proposed benefits of limiting complications  (19).  However, 
despite the recent surgical advances older patients have less functional reserve than younger 
patients and perioperative complications in this cohort are often poorly tolerated. Our 
preoperative tool may help to carefully select elderly patients appropriate for surgical 
intervention and to provide patients with appropriate counseling of the risks of perioperative 
mortality based on preoperative patient and tumor characteristics.   
 
Moving forward, it is our hope to be able to confirm the external validity of our nomogram on a 
separate dataset.   Ultimately, we plan to evaluate if these pre-operative factors are associated 
with disease specific and overall survival.  Confirming these initial observations would aid in 
patient selection for surgical intervention, especially in those with advanced age, by evaluating 
the competing causes of morbidity and mortality. With future institutional collaboration, we hope 
to assess whether age, morbidity, demographics and other significant variables influence long-
term results.  
Conclusions: 
90-day surgical mortality in patients undergoing surgery for localized non-metastatic renal cell 
carcinoma is independently associated with patient age, gender, stage, race and co-morbidities.  
Of all these factors, advanced patient age is the most predictive of surgical short-term mortality.  
Age appears to be more important that tumor biology and patient co-morbidities.  We created a 
nomogram to help in pre-operative patient counseling and risk analysis prior to surgical 
intervention. 
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